[SCHEDULE 14A INFORMATION Check the appropriate box: [ ] Preliminary Proxy Statement [ ] [ ] Definitive Proxy Statement [X] Definitive Additional Materials [ ] Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. __________________________________________________________ Payment of Filing Fee (Check the appropriate box): [ ] No fee required [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1)]
[SCHEDULE 14A INFORMATION Check the appropriate box: [ ] Preliminary Proxy Statement [ ] [ ] Definitive Proxy Statement [X] Definitive Additional Materials [ ] Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. __________________________________________________________ Payment of Filing Fee (Check the appropriate box): [ ] No fee required [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1)]
[SCHEDULE 14A INFORMATION Check the appropriate box: [ ] Preliminary Proxy Statement [ ] [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. __________________________________________________________ Payment of Filing Fee (Check the appropriate box): [ ] No fee required [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1)]
[SCHEDULE 14A INFORMATION Check the appropriate box: [ ] Preliminary Proxy Statement [ ] [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. __________________________________________________________ Payment of Filing Fee (Check the appropriate box): [ ] No fee required [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1)]
[Company Contact Mar. 31, 2011 (PR Newswire) -- China Biologic Products Reports Record Sales and Net Income for 2010 Tai'an, Shandong Province, PRC, March 31, 2010 – China Biologic Products, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), one of the leading plasma-based biopharmaceutical companies in the People’s Republic of China (“PRC”), today reported record sales and net income for] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): April 1, 2011 ( March 31, 2011) CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or]
[Company Contact Mar. 31, 2011 (PR Newswire) -- China Biologic Products Reports Record Sales and Net Income for 2010 Tai'an, Shandong Province, PRC, March 31, 2010 – China Biologic Products, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), one of the leading plasma-based biopharmaceutical companies in the People’s Republic of China (“PRC”), today reported record sales and net income for] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): April 1, 2011 ( March 31, 2011) CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or]
[FORM 10-K/A (Amendment No. 2) (Mark One) [X] December 31, 2009 Commission File No. 001-34566 CHINA BIOLOGIC PRODUCTS, INC. DELAWARE 75-2308816 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) No. 14 East Hushan Road, (+86) 538-620-2306 Title of each class Name of each exchange on which registered Common Stock, Par Value $0.0001 The NASDAQ Stock Market] [CERTIFICATIONS I, Chao Ming Zhao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Y. Tristan Kuo, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Chao Ming Zhao Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Y. Tristan Kuo Chief Financial Officer (Principal Financial and Accounting Officer)]
[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): March 31, 2011 ( March 30, 2011) CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or]
[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): March 31, 2011 ( March 30, 2011) CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or]
[FORM 10-K (Mark One) December 31, 2010 For the fiscal year ended: For the transition period from ____________to _____________ No. 001-34566 Commission File CHINA BIOLOGIC PRODUCTS, INC. Delaware 75-2308816 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) No. 14 East Hushan Road Peoples Republic of China (+86) 538-620-2306 Title of each class Name of each exchange] [CHINA BIOLOGIC PRODUCTS, INC. China Biologic Products, Inc. is the parent. The subsidiaries of China Biologic Products, Inc. as of December 31, 2010 are as follows: Jurisdiction of Ownership Interest Name Incorporation or Held By Its Organization Immediate Parent Logic Express Ltd. BVI 100.0% Logic Holdings (Hong Kong) Ltd. HK 100.0% Logic Taibang Biological Institute Beijing Beijing PRC 100.0% Logic] [The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-171069) on Form S-3 of China Biologic Products, Inc. (the "Company") of our reports dated March 31, 2011, with respect to the consolidated balance sheet of the Company and subsidiaries as of December 31, 2010, and the related consolidated statements of income, stockholders equity] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of We consent to the use of our report dated March 23, 2010, except for the effects on the consolidated financial statements of the restatement described in Note 2, as to which the date is March 31, 2011, with respect to the consolidated balance sheets of China Biologic] [CERTIFICATIONS I, Chao Ming Zhao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Yu-Yun Tristan Kuo, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Chao Ming Zhao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Yu-Yun Tristan Kuo Chief Financial Officer (Principal Financial and Accounting Officer)]
